lutetium has been researched along with technetium tc 99m medronate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ando, A; Ando, I; Fujita, N; Kataiwa, A; Kazuma, K; Kinuya, S; Nakagawa, M; Tonami, N | 1 |
| Ahmadzadehfar, H; Essler, M; Gaertner, F; Schlenkhoff, CD; Schmidt, M | 1 |
2 other study(ies) available for lutetium and technetium tc 99m medronate
| Article | Year |
|---|---|
177Lu-EDTMP: a potential therapeutic bone agent.
Topics: Animals; Beta Particles; Bone and Bones; Bone Neoplasms; Femur; Gamma Rays; Humans; Lutetium; Male; Organometallic Compounds; Organophosphorus Compounds; Pain; Palliative Care; Radiopharmaceuticals; Rats; Rats, Wistar; Technetium Tc 99m Medronate; Time Factors; Tissue Distribution | 1998 |
Positive Influence of 177Lu PSMA-617 Therapy on Bone Marrow Depression Caused by Metastatic Prostate Cancer.
Topics: Aged; Anemia; Antineoplastic Agents; Bone Marrow Diseases; Bone Neoplasms; Compassionate Use Trials; Dipeptides; Edetic Acid; Gallium Isotopes; Gallium Radioisotopes; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Oligopeptides; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Radium; Technetium Tc 99m Medronate | 2016 |